GLP-3R Long Term Effects: 2026 Research & Expert Care

Written by: Ellie Pranckevicius, FNP-BC, Aesthetic Nurse Practitioner & Aesthetic Injector | Facial Restoration & Regenerative Injectable Specialist, Mirror Plastic Surgery | Last updated: August 20, 2026

Key Takeaways on Retatrutide and Mirror Plastic Surgery Care

• Retatrutide (GLP-3R) remains investigational as of August 2026, with no FDA approval expected until at least Q1 2027 and no long-term safety data beyond 80 weeks of use.
• Phase 3 trials show impressive weight-loss results, with the highest dose achieving up to 28.3% mean weight loss at 80 weeks and extended treatment showing even greater results in certain subgroups.¹
• Unique side effects include dose-dependent heart-rate elevation and dysesthesia (abnormal skin sensations), which call for careful cardiovascular and sensory monitoring.
• Weight regain is expected after discontinuation, with data from similar GLP-1 agents showing 50–60% of lost weight typically regained within one year without structured maintenance.
• Patients considering GLP-3R therapy should consult Mirror Plastic Surgery for medically supervised protocols that include baseline screening, ongoing monitoring, and a discontinuation plan, and can book an appointment with Ellie to discuss whether retatrutide is appropriate for their health profile.

How Retatrutide Performs in 2026 Trials (48–80 Weeks)

Five positive Phase 3 trials have now reported for retatrutide. The pivotal TRIUMPH-1 obesity trial enrolled 2,339 adults and produced the following mean weight-loss results at 80 weeks:

Dose	Mean Weight Loss (%)	Mean Weight Loss (lbs)	≥30% TBWL Achieved
Placebo	2.2%	5.5 lbs	N/A
4 mg	19.0%	47.2 lbs	Not reported at this dose
9 mg	25.9%	64.4 lbs	Not reported at this dose
12 mg	28.3%	70.3 lbs	45.3% of participants

A pre-specified extension in participants with BMI ≥35 who continued retatrutide 12 mg to 104 weeks reported mean weight loss of 30.3% (85.0 lbs), with no plateau observed.¹ This result represents a subgroup extension rather than full two-year data for all trial participants, so generalizability remains incomplete.

In the TRANSCEND-T2D-1 Phase 3 trial, retatrutide lowered A1C by an average of 1.7% to 2.0% across doses at 40 weeks, and participants taking the 12 mg dose lost an average of 36.6 lbs (16.8%).¹

In the July 2026 Phase 3 TRIUMPH-2 trial, retatrutide produced up to 20.8% weight loss at 80 weeks in overweight or obese adults with type 2 diabetes.¹ TRIUMPH-3 showed up to 22.6% in patients with severe obesity and cardiovascular disease.¹ As of that announcement, Eli Lilly had not yet submitted a biologics license application, citing the need for additional manufacturing and quality-control data, with submission planned for Q1 2027.

For context, tirzepatide produced mean weight loss ranging from 16.0% to 22.5% at 72 weeks in SURMOUNT-1.¹ Cross-trial comparisons are indirect because TRIUMPH-1 and SURMOUNT-1 used different durations, lifestyle protocols, and baseline BMI distributions. No head-to-head randomized trial of retatrutide versus tirzepatide has reported results as of August 2026, and the registered direct comparison is TRIUMPH-5.

Side Effects: GI Issues, Heart Rate Changes, and Dysesthesia

Gastrointestinal adverse events are the most common side effects across all retatrutide trials and occur primarily during dose escalation.

Heart-rate elevation is a clinically relevant signal specific to retatrutide’s glucagon receptor component. Phase 2 data showed dose-dependent mean increases in resting heart rate at week 48 versus placebo, with baseline around 72–73 bpm. A separate analysis reported a peak increase of approximately 6.7 bpm at 12 mg around week 24. Glucagon receptors are expressed in sinoatrial tissue and increase heart rate through cAMP signaling, a mechanism absent in dual GLP-1/GIP agonists such as tirzepatide.

In one Phase 3 trial, arrhythmias were reported in approximately 1.7% of retatrutide recipients compared with 0% on placebo, and none were classified as serious. No increase in major adverse cardiovascular events has been observed in available data, though no dedicated cardiovascular outcomes trial has been completed. The TRIUMPH-Outcomes trial, which will evaluate MACE and kidney outcomes, is not expected to report until approximately 2028–2029.

Dysesthesia (abnormal skin sensations including tingling, burning, or numbness) emerged as a dose-dependent signal unique to retatrutide among incretin-based therapies. In TRIUMPH-1, dysesthesia occurred in 8.8% of participants at 9 mg and 20.9% at 12 mg versus 0.7% on placebo, matching the 12 mg rate observed in TRIUMPH-4. Most events were mild and resolved during treatment.

Additional signals reported across trials include pancreatitis and gallbladder events, with rates similar to other incretin therapies. No cases of medullary thyroid carcinoma have been reported. Patients warranting particular caution include those with baseline resting heart rate above 100 bpm, recent acute coronary syndrome, NYHA class III–IV heart failure with instability, significant ventricular arrhythmia history, active hyperthyroidism, pheochromocytoma, or recent hemodynamically unstable stroke.

Protecting Muscle and Metabolism During Treatment

Lean body mass preservation is a central concern with any aggressive weight-loss pharmacotherapy. Previous studies indicate that lean body mass, including muscle, can constitute up to 40% of total weight lost during GLP-1R agonist treatment, with some reports suggesting 40–60% of lost weight is muscle. No retatrutide-specific body-composition data from Phase 3 trials have been published as of August 2026, so these figures are extrapolated from the broader incretin class.

Retatrutide’s glucagon receptor activity increases hepatic energy expenditure and lipolysis, mechanisms not present with tirzepatide, which may influence the fat-to-lean mass ratio of weight lost. This effect remains speculative until dedicated body-composition substudies report results.

Metabolic monitoring during retatrutide use should address the following domains:

• Lean mass and body composition (DEXA or validated bioimpedance at baseline and every 12–16 weeks)
• Resting heart rate and blood pressure at each follow-up visit
• Liver function (ALT, AST), as Phase 2 data showed transient ALT elevations that normalized by week 24
• Kidney function (GEFR, creatinine) given ongoing TRIUMPH-Outcomes renal endpoint evaluation
• Fasting glucose, HbA1c, and insulin resistance markers
• Lipid panel (non-HDL cholesterol, triglycerides), as TRIUMPH-1 showed significant improvements in both
• Thyroid function, given class-level precautions for incretin therapies
• Skin sensation assessment for dysesthesia at each visit

Resistance training and adequate protein intake are standard adjuncts to any GLP-class protocol to help mitigate lean mass loss. Because each patient’s baseline fitness, musculoskeletal status, and caloric trajectory differs, these behavioral components require individualized guidance rather than a one-size-fits-all prescription.

What to Expect When GLP-3R Therapy Stops

No published clinical trial has specifically examined weight regain after retatrutide discontinuation. The TRIUMPH-4 trial reported 68-week continuous-treatment results but included no randomized withdrawal phase. All discontinuation projections are extrapolated from semaglutide and tirzepatide withdrawal studies.

The available data from analogous agents are consistent:

• In the STEP 1 trial extension, participants who discontinued semaglutide 2.4 mg after 68 weeks regained approximately two-thirds of their lost weight within 12 months,¹ with cardiometabolic improvements reversing substantially and hunger returning to near-baseline levels within weeks.
• In SURMOUNT-4, participants randomized to placebo after tirzepatide treatment regained roughly half their lost weight over 52 weeks,¹ while those continuing treatment maintained or increased weight loss.
• A University of Cambridge nonlinear meta-regression of six randomized controlled trials involving more than 3,200 individuals found that people regain on average 60% of lost weight by 52 weeks after stopping GLP-1 receptor agonist therapies,¹ with regain beginning to plateau around 60 weeks and tapering at approximately 75% of original weight loss, meaning individuals may sustain roughly 25% of treatment-related weight reduction long-term.

These findings consistently demonstrate that weight regain is substantial and begins rapidly after discontinuation. Weight regain after GLP-1 class discontinuation reflects metabolic adaptation (reduced resting energy expenditure beyond body-mass loss), hormonal normalization (ghrelin returning to pre-treatment levels), hypothalamic set-point defense, and reversion of appetite-suppressed eating behaviors. Because retatrutide engages glucagon receptors in addition to GIP and GLP-1, withdrawal effects could theoretically differ from single- or dual-agonist therapies, though any durable metabolic remodeling from glucagon agonism remains speculative.

Eli Lilly has registered NCT06859268, an 80-week lead-in plus 36-week randomized maintenance study specifically designed to evaluate whether lower-dose or altered retatrutide regimens can preserve weight loss after initial treatment. Results are not yet available.

Obesity is a chronic disease analogous to hypertension or type 2 diabetes. Most patients who achieve significant weight loss with retatrutide will require ongoing pharmacotherapy or a structured maintenance protocol to sustain results.

Book an appointment with Ellie to build a discontinuation and maintenance plan before starting any GLP-3R protocol, rather than waiting until weight regain begins.

Why Medical Supervision Is Essential for Retatrutide

Retatrutide is not FDA-approved as of August 2026. Eli Lilly plans to file a biologics license application in Q1 2027, citing the need for additional manufacturing and quality-control data. Any retatrutide available outside of Lilly’s registered clinical trials is compounded or sourced through channels that carry meaningful quality and dosing uncertainty.

The risks of unsupervised use are concrete and clinically relevant. They include:

• Unknown product purity and active-ingredient concentration from unverified compounders
• Incorrect dose escalation schedules that amplify GI and cardiovascular adverse events
• Absence of baseline screening for contraindications such as resting tachycardia, arrhythmia history, thyroid disease, or active gallbladder disease
• No monitoring for dysesthesia, liver enzyme elevation, or lean mass loss
• No structured plan for discontinuation or weight-maintenance transition

Retatrutide is recommended only for low cardiovascular and kidney risk patients with obesity who prioritize maximal weight loss. Patients with established cardiovascular disease, heart failure, or chronic kidney disease should use agents with proven cardiorenal benefits instead. This risk stratification requires clinical judgment, not a self-assessment questionnaire.

How Mirror Plastic Surgery Manages GLP-3R Treatment in 2026

Ellie Pranckevicius, FNP-BC, leads all peptide and GLP-3R protocols at Mirror Plastic Surgery. A board-certified Family Nurse Practitioner, Ellie holds a Master’s in Nursing from the University of South Florida and spent four years in the Neuroscience ICU at Tampa General Hospital managing complex metabolic and physiologic cases. She began her career as a licensed esthetician at a high-end medical spa in Boston, which gives her a dual command of aesthetic goals and clinical science that is rare among peptide practitioners.

Her approach centers on education and clear communication. She explains the physiology behind every recommendation in plain terms and tells patients when a protocol is not yet appropriate for them.

Mirror Plastic Surgery’s GLP-3R monitoring protocol includes the following elements:

• Baseline consultation (30–60 minutes): Full medical history, contraindication screening, resting heart rate and blood pressure, and review of existing labs or ordering of a comprehensive panel (thyroid, liver, kidney, fasting glucose, HbA1c, lipids, hormone panel)
• Dose escalation oversight: Structured escalation schedule with check-ins at weeks 4, 8, and 16 to assess GI tolerance, heart rate trends, and dysesthesia
• Ongoing lab monitoring: Repeat metabolic panel at 12 weeks and every 16 weeks thereafter, with body-composition assessment at baseline and every 12–16 weeks
• Cardiovascular surveillance: Resting heart rate logged at every visit, and patients with borderline baseline heart rate or arrhythmia history evaluated individually before initiation
• Remote access: Direct text access to Ellie 24/7 for questions, side-effect triage, and refill coordination, with telemedicine appointments available across all 50 U.S. states
• Peptide sourcing: All compounds sourced from reputable providers with documented batch testing for purity and accurate dosage
• Maintenance planning: Structured transition protocol initiated before any planned discontinuation to help mitigate weight regain

Mirror Plastic Surgery performs one to two procedures per day by design, which ensures that Ellie’s attention is not divided across a high-volume patient roster. This concierge model means protocol adjustments, lab reviews, and side-effect management receive the same individualized focus as the initial consultation.

Book an appointment with Ellie to receive a comprehensive baseline assessment and a GLP-3R protocol built around your specific lab results, cardiovascular profile, and weight-loss goals.

Frequently Asked Questions About Retatrutide at Mirror Plastic Surgery

Is retatrutide (GLP-3R) FDA-approved in 2026?

No. As of August 2026, retatrutide remains an investigational molecule. Eli Lilly has announced plans to file for FDA approval in early 2027 following five positive Phase 3 trials. Any retatrutide available outside of Lilly’s registered clinical trials is compounded. Mirror Plastic Surgery sources compounded peptides exclusively from providers with documented batch testing and operates under full medical supervision to help mitigate the risks associated with the current pre-approval status.

How does retatrutide’s weight loss compare to Ozempic or Wegovy?

Direct head-to-head trials have not been completed. Based on available Phase 3 data, retatrutide 12 mg produced mean weight loss of 28.3% at 80 weeks in TRIUMPH-1, compared with approximately 14–15% for semaglutide 2.4 mg at 68 weeks in STEP 1 and 20.9% for tirzepatide 15 mg at 72 weeks in SURMOUNT-1.¹ These comparisons are indirect because the trials used different durations, baseline BMI distributions, and lifestyle protocols. Retatrutide’s added glucagon receptor activity increases hepatic energy expenditure and lipolysis, which is the primary pharmacological explanation for the larger observed weight loss.

What are the most important safety unknowns for GLP-3R as of 2026?

The most significant unknowns are long-term cardiovascular outcomes and safety beyond approximately 80 weeks of continuous use. The TRIUMPH-Outcomes cardiovascular and renal outcomes trial, enrolling approximately 10,000 participants, remains ongoing with results expected around the same timeframe as mentioned earlier. A preliminary cardiovascular outcomes dataset reported in July 2026 showed patients on retatrutide had a 12% higher risk of the three most severe events (heart attack, stroke, and death) compared with placebo, though the dataset was limited and overall major cardiovascular events occurred less frequently than expected in both groups. Additional unknowns include the long-term trajectory of dysesthesia, the fat-to-lean mass ratio of regained weight after discontinuation, and whether glucagon receptor agonism produces durable metabolic remodeling beyond the treatment period.

Will I regain weight if I stop taking retatrutide?

Based on data from analogous GLP-1 class agents, significant weight regain is expected after discontinuation without a structured maintenance plan. The Cambridge meta-regression mentioned earlier found that roughly 60% of lost weight returns within a year, with long-term retention settling around 25% of the original treatment effect.¹ No retatrutide-specific discontinuation trial has been published. Eli Lilly has registered a maintenance study (NCT06859268) to evaluate lower-dose strategies for preserving weight loss, but results are not yet available. Mirror Plastic Surgery builds a maintenance transition plan into every GLP-3R protocol from the outset.

Who is not a good candidate for retatrutide?

Patients with established cardiovascular disease, heart failure, chronic kidney disease, or a history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 should not use retatrutide outside of closely monitored clinical settings, and many should use agents with proven cardiorenal outcomes data instead. Additional contraindications requiring individual evaluation include resting heart rate above 100 bpm, significant ventricular arrhythmia history, active hyperthyroidism, pheochromocytoma, active or recent pancreatitis, and symptomatic gallbladder disease. Ellie Pranckevicius conducts a full contraindication screen and baseline lab review before initiating any GLP-3R protocol at Mirror Plastic Surgery.

Medical and Regulatory Disclaimer

The information in this article is intended for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Retatrutide is an investigational compound that has not been approved by the U.S. Food and Drug Administration as of August 2026. It is not commercially available through standard pharmacy channels. All clinical data cited reflect Phase 2 and Phase 3 trial results published or announced through August 2026, and findings are subject to revision as additional trial data become available. Long-term safety data beyond approximately 80 weeks of continuous use have not been established in completed trials. Individual results vary. Consult a qualified, licensed healthcare provider before initiating any peptide or pharmacological weight-management protocol. Mirror Plastic Surgery’s GLP-3R protocols are provided under the supervision of Ellie Pranckevicius, FNP-BC, and are tailored to each patient’s individual health profile, lab results, and medical history. This article will be updated as new Phase 3 data are published. Last reviewed: August 2026.

---